Surbhi Sarna is a Group Partner at YC. She was the founder and former CEO of nVision Medical, which developed a first-in-kind microcatheter for the detection of ovarian cancer. After raising $17M in venture funding, completing three clinical trials, and obtaining two first-in-class FDA approvals, nVision was acquired by Boston Scientific (NYSE: BSX) for $275M, more than 15X money-in. Surbhi stayed at Boston Scientific for two years, running the 150+ person commercial organization in preparation for launch. She sits on both private and public company boards.
YC stats
- Surbhi is on the board of seven companies, ranging from a Series A startup to a publicly traded company with a $12B market cap.
- Surbhi has done more than 1,300 office hours over the course of 6 batches at YC.
- The YC companies Surbhi has worked with are worth a combined $6 billion.
- She's advised top YC alumni including:
In the news
- Fortune: Y Combinator group partner Surbhi Sarna says work-life balance is a misnomer
- Forbes: How An Entrepreneur Learned The Art Of The Pitch And Sold Her Startup For $275M
- The Second City: Getting to yes, and
- Forbes: Y Combinator Names Surbhi Sarna Its First-Ever Partner For Healthcare And Biotech
- Forbes: A 32-Year-Old's Startup, Inspired By A Health Scare, Sells For $275 Million
Videos
YC Bio Fireside Series
Underrated but Unbeatable: A $275M healthcare startup success
Surbhi Sarna on nVision Medical